TearClear, a late clinical stage ophthalmic pharmaceutical company, has filed an Investigational New Drug (IND) application to conduct a registrational study for its lead glaucoma candidate, TC-002 latanoprost ophthalmic solution, 0.005%.
Approximately 30%-40% of patients who rely on preserved, chronic glaucoma therapies show signs of moderate to severe Ocular Surface Disease (OSD)1. Studies have suggested that removal of preservatives may be beneficial for the ocular health of such patients. To date, options for these patients have been less than adequate.
TearClear is the first and only company to develop products that keep BAK-preserved formulations safely in the bottle and deliver pristine, preservative-free drops of trusted medicines to the eye.
“We are confident that improving the health of the ocular surface matters,” Stuart Raetzman, TearClear’s CEO stated. “Responding to that unmet need has propelled us to this important milestone and it is what drives us to expand our efforts for other glaucoma therapies and to important therapies beyond glaucoma that intersect with OSD.”
About TearClear
TearClear is an emerging ophthalmic pharmaceutical company with the goal of disrupting the way current topical medications are delivered to the ocular surface. Our lead product candidates in glaucoma will pave the way for future indications across multiple programs in development. This first in class platform of drugs enables medication delivery to ultimately enhance patient safety and compliance by capturing preservatives before they reach the ocular surface. TearClear is based in Boston, MA. For more information, visit TearClear and connect with us on LinkedIn.
About Preservative Free
Preservatives, such as benzalkonium chloride (BAK), are necessary in ophthalmic solutions to maintain sterility. However, on the ocular surface, they have been reported to be associated with adverse effects like hyperemia, tear film instability and conjunctival inflammation potentially leading to meibomian gland dysfunction (MGD). By removing preservatives from the ocular surface, the potential for long term deleterious effects on the eye are reduced. TearClear offers the only means of delivering a preservative-free dose directly from preserved solutions.
TearClear Press Contact
- Patrick Crowley